Nucala Among Flurry Of New Respiratory Products On Indian Horizon
Executive Summary
Novel asthma/COPD drugs, including GlaxoSmithKline’s biologic therapy Nucala, are on the horizon in India, set to expand treatment options in the competitive segment. But pricing is expected to be key in pushing uptake, and health care delivery in asthma/COPD in India remains rather sub-optimal, notwithstanding the interest around new launches.
You may also be interested in...
Portfolio Streamlining At GSK India But Long Term Commitment Intact
GlaxoSmithKline has initiated portfolio rationalization measures in India as the British multinational reshapes its emerging markets business model with an eye on driving sustained profitable growth. But the company has also underscored its long-term commitment to the country, where it expects to build on its “strong heritage” and expand patient access.
Novartis Progressing Trials For Oral Asthma Therapy In India
Novartis is advancing studies with its experimental asthma therapy fevipiprant in India, amid significant expectations around its possible impact on market dynamics including aspects such as the potentially shared patient pool with certain biologics.
INTERVIEW: A Revolution At GSK India
Brace for GSK India's new avatar. The British multinational is revamping its business model in India and donning a new approach to create, deliver and capture value via a "one team" effort as it strives to emerge as the fastest growing pharma multinational in the country by 2020.